This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Exit highlight in Life Sciences: GreenGate Partners advises HTGF on the sale of Tubulis to Gilead Sciences
GreenGate Partners is pleased to have advised High-Tech Gründerfonds (HTGF) on the sale of its portfolio company Tubulis to Gilead Sciences.
Gilead has entered into a definitive agreement to acquire Tubulis, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), for USD 3.15 billion upfront plus up to USD 1.85 billion in milestone payments. The transaction represents the highest-valued exit in HTGF’s history and the third unicorn exit in HTGF’s life sciences portfolio.
Following completion of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with its Munich site continuing to serve as a hub for ADC innovation.
The transaction highlights the importance of long-term partnership between investors and founders in translating scientific innovation into impactful therapies and meaningful value creation.
More Deal News
Sorry, no posts matched your criteria.
Advisors GreenGate Partners
Dr. Tobias Schönhaar, LL.M. (Bond) (Partner / Corporate)
Constantin Forstner (Senior Associate / Corporate)